Diagnosis of peripheral pulmonary lung nodules is a clinical challenge requiring a multi-disciplinary approach. Robotic bronchoscopy (RB) has come into the forefront of novel diagnostic procedures allowing for visualization and stable access to distal airways providing better access to nodules. However, limited data currently exist as to the diagnostic yield of RB and the learning curve required to become proficient. METHODS:This was a retrospective, single center study utilizing the robotic bronchoscope (Ion, Intuitive Medical) to sample peripheral pulmonary nodules. Data collected include nodule characteristics, length of procedure, use of linear endobronchial ultrasound (EBUS), and overall yield for malignant and benign nodules. Results from the first 6 months of use were compared to results from the last 8 months. Samples which were atypical or did not show a definite benign or malignant diagnosis were classified as non-diagnostic. Nodules were classified into true positive (TP), true negative (TN), or false negative (FN). TP were nodules with biopsy positive carcinoma or a defined benign diagnosis. TN nodules were non-diagnostic that had a benign diagnosis confirmed by resection, or follow-up imaging demonstrating decreased size of the nodule or a minimum of 6 months of stability. FN nodules were non-diagnostic and subsequently found to be cancer or treated as such with empiric radiation.RESULTS: 95 patients with 103 nodules were biopsied between February 2020 and April 2021. Median lesion size was 19 mm (range 7-69mm). Based on RB 9(8.7%) of biopsies were benign, 60(58%) malignant and 34(33%) non-diagnostic. Benign RB diagnosis included hamartoma, fungal elements, organizing pneumonia and granulomas. In the non-diagnostic group 23/33 had complete follow up data and 13 (57%) were confirmed as benign.When comparing the first 6 months to the last 8 months the TP rate improved from 20/33 (61%) to 49/60 (82%) and the FN rate decreased from 4/33(12.1%) to 6/60 (10%) (p¼0.0415). A total of 70 nodules were ultimately defined as malignant. RB confirmed diagnosis in 60(86%) of those. In the first 6 months malignancy was confirmed in 19/23 (83%) and this improved to 41/47 (87%; p¼0.72).The average procedure time for RB did not differ significantly between the first 6 months and thereafter (81.9min vs 70.9min, p =0.1300). The procedure time for RB with EBUS decreased significantly from 138.9min to 104.5min (p = 0.0081). CONCLUSIONS:In this study, a learning curve effect was seen with significant improvements in TP/FN rates, and shorter procedure times when performed in conjunction with EBUS. In patients with cancer, RB is even more effective with yield as high as 87%.CLINICAL IMPLICATIONS: Our initial experience shows excellent results that may be superior to electromagnetic navigation bronchoscopy. A learning curve was demonstrated.
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection can vary from asymptomatic to severe symptoms. It can lead to respiratory failure and acute respiratory distress syndrome requiring intubation and mechanical ventilation. Triaging patients is key to prevent spread, conserving medical resources, and providing appropriate care. The treatment of these patients remains supportive. Respiratory failure due to the virus should be managed by providing supplemental oxygen and early intubation. Some patients develop acute respiratory distress syndrome and refractory hypoxemia. In this article, we review the 2 phenotypes of respiratory failure, mechanical ventilation and the management of refractory hypoxemia.
Acute respiratory distress syndrome (ARDS) was first described in 1967 by Ashbaugh and colleagues. Acute respiratory distress syndrome is a clinical syndrome, not a disease, and has no ideal definition or gold standard diagnostic test. There are multiple causes and different pathways of pathogenesis as well as various histological findings. Given these variations, there are many clinical entities that can get confused with ARDS. These entities are discussed in this article as “Mimics of ARDS.” It imperative to correctly identify ARDS and distinguish it from other diseases to implement correct management strategy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.